Blog

  • Peek inside the California Science Center’s rocket-filled space expansion

    Peek inside the California Science Center’s rocket-filled space expansion

    One of my biggest L.A. regrets? Letting the potential for traffic scare me away from seeing Space Shuttle Endeavour paraded across the city’s surface streets. So in the 13 years since, I’ve tried to steep myself in as many…

    Continue Reading

  • Live updates, top moments from a 9-game night

    Live updates, top moments from a 9-game night

    Amen Thompson and the Houston Rockets face Donovan Mitchell and the Cavaliers to open tonight’s ESPN doubleheader.

    Enjoy the best of Wednesday’s slate with the NBA.com live blog, featuring all of the meaningful moments, performances,…

    Continue Reading

  • Pinprick blood test could detect disease 10 years before symptoms appear, study finds | Medical research

    Pinprick blood test could detect disease 10 years before symptoms appear, study finds | Medical research

    The world’s largest study into key substances in the bloodstream has paved the way for a swathe of pinprick tests that can detect early signs of disease more than a decade before symptoms appear, researchers say.

    Work on the tests follows the…

    Continue Reading

  • South Korean banks take the lead to bridge gender inequalities

    South Korean banks take the lead to bridge gender inequalities

    MJ Song, a South Korean working mother with a four-year-old son, considers herself lucky because she has been able to work for one company for more than 15 years without her career being hindered by starting a family.

    Her employer, a unit of Shinhan Financial Group, offers generous pay and benefits such as baby bonuses, childcare allowances and flexible working, allowing her to balance work and family life in a country notorious for long working hours and rigid corporate cultures.

    Song took two years of maternity leave after her son was born then worked for four hours a day for a year, receiving half her normal salary. Shinhan also allows women to work two hours fewer a day during pregnancy and employees with children in their first two years of primary school to start work an hour later.

    “I am satisfied with my job as the salary is high with a lot of benefits for working moms,” says Song. “The workload is heavy, but my PC gets automatically turned off after 6pm. It has been relatively easy to balance work and family life, while most of my friends have quit their jobs after childbirth.”

    Korean financial groups have been one of the most coveted workplaces among female graduates, thanks to their competitive pay and childcare-related perks, despite technology causing wider cuts to the industry’s workforce.

    Financial groups are also notable for their relatively high number of female workers in the male-dominated, manufacturing-driven economy. Female workers account for more than half of the financial sector workforce, about double the average in South Korea’s 500 biggest companies by sales, according to research group Leaders Index.

    Labour expert Bae Kyu-shik says: “Financial companies have become good employers for women, thanks to their high pay and strong internal welfare benefits.”

    Some content could not load. Check your internet connection or browser settings.

    Women boast an average 14.5 years of service at Korean banks versus men’s 15.4 years, while women’s annual salaries average Won96.9mn ($66,100), compared with Won128.4mn for men, Leaders Index data shows. Similar to the manufacturing sector, most Korean bank staff retire in their mid-fifties, but they usually receive generous severance pay and packages that amount to several years’ salary if they retire early.

    Foreign lenders in Korea, such as Citibank and Standard Chartered, also offer flexible work for parents with young children, reduced hours for pregnant women and longer paternity leave. They also offer baby bonuses, although these are less generous than those from local counterparts.

    As the country addresses the world’s lowest fertility rate of 0.75 per cent, Korean banks have been at the forefront of the government-led initiative to solve it by offering various childcare benefits. The demographic crisis poses a huge challenge for sustaining economic growth and providing pensions and healthcare for an ageing population.

    But economic and cultural discrimination means many Korean women remain reluctant to marry and have children. South Korea has the highest gender pay gap among rich countries, with women paid almost a third less than men, despite their above-average level of tertiary education, reports the OECD.

    South Korea’s male-oriented corporate culture and working hours — some of the longest in the OECD — remain a barrier to women’s labour participation, with more than 15 per cent of married women quitting jobs after having children, according to government data, while those who keep working struggle to progress in their careers.

    The government has been spending heavily to counter the low birth rate, with financial groups going beyond national requirements by offering baby bonuses worth tens of thousands of dollars and up to three years of maternity leave, as well as flexible working for parents with children aged below 10 at school. Statutory leave is up to a year and a half.

    Banks such as KB Kookmin and Woori last year started offering up to three years of “parental resignation” programmes for employees with children aged below seven, on top of a two-year childcare leave, with the guarantee of returning to the same position.

    There are limits, however. Despite the government policy to support paternity leave — a father with a child under eight can take up to a year and a half off — men taking the leave remains at a single-digit rate at most banks because of social norms that still regard childcare and household duties as a woman’s job.

    Some content could not load. Check your internet connection or browser settings.

    Despite the high proportion of female workers, few are at executive level in the financial sector, as most women work in retail banking, rather than higher-margin businesses such as corporate and investment banking, which are seen as better for promotions.

    “There are equal opportunities for hiring, but they are not equal positions,” says Park Ju-geun, head of Leaders Index, noting there is still a 30 per cent pay gap in banking. “Women still don’t have many opportunities for promotions as they are barred from key operations like strategic planning, sales, marketing and treasury departments.”

    The number of female executives is increasing after legislation in 2022 banned single-gender boards at companies with assets of more than Won2tn. But women still hold only 12.7 per cent of executive positions at South Korean banks, although this is higher than the 8.1 per cent average across the country’s 500 biggest companies, according to Leaders Index.

    There are signs of improvement, however. Internet-only lender Toss Bank and the South Korean unit of Citibank both have female chief executives, while some banks offer leadership and mentoring programmes for women.

    “Women are often hired for supplementary positions, so most fail to move up the ladder,” says Oh Hee-jung, deputy head of the Korean Finance & Service Workers’ Union. “Like in other sectors, the glass ceiling still exists in the financial sector, with most women struggling to shatter it.”

    Continue Reading

  • Electroconvulsive therapy may have more adverse effects than thought | Science

    Electroconvulsive therapy may have more adverse effects than thought | Science

    Electroconvulsive therapy could be causing a wider range of adverse effects when used to treat depression than previously understood, according to a paper that calls for the practice to be suspended pending more robust research.

    Although short-…

    Continue Reading

  • Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints

    SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) met the primary endpoints and all key secondary endpoints. Innovent plans to submit the new drug application (NDA) of mazdutide 9 mg for weight management to the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) in the near term.

    GLORY-2 (NCT06164873) is a Phase 3 clinical study to evaluate the efficacy and safety of mazdutide 9 mg combined with lifestyle intervention versus placebo in Chinese adults with obesity (BMI ≥30 kg/m²). The study enrolled 462 participants (including 16% with type 2 diabetes), randomized in a 2:1 ratio to receive mazdutide 9 mg group or placebo in the 60-week double-blind treatment period (mean baseline weight: 94.0 kg; mean BMI: 34.3 kg/m²).

    During the treatment period, participants in the mazdutide group exhibited continuous weight loss, with no plateau observed in Week 60. At Week 60, the mazdutide 9 mg group achieved a mean weight reduction of 18.55%, compared to 3.02% in the placebo group. 44.0% of participants in the mazdutide 9 mg group achieved a weight reduction of 20% or more, versus 2.6% in the placebo group (P<0.0001 for all comparisons). The key secondary endpoints demonstrated that among participants without type 2 diabetes, the mazdutide 9 mg group showed a mean weight reduction of 20.08% at Week 60 (placebo: 2.81%), with 48.7% of participants achieving a weight reduction of 20% or more (placebo: 3.1%; P<0.0001).

    Furthermore, all key secondary endpoints of the study were met, including other body weight endpoints, waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and serum uric acid levels. Mazdutide 9 mg demonstrated superiority to placebo in all the above weight-loss and cardiometabolic endpoints.

    This study also evaluated liver fat content using MRI-PDFF in a subset of participants. Among participants (without type 2 diabetes) with baseline liver fat content ≥10%, the mean percent change in liver fat content from baseline to week 60 was -71.9% in the mazdutide 9 mg group compared with 5.1% in the placebo group.

    Mazdutide 9 mg demonstrated favorable tolerability and safety profiles, with no new safety signals identified. The majority of gastrointestinal adverse events were mild to moderate in severity and transient in nature. The proportion of participants who discontinued treatment prematurely due to adverse events was 2.9% in the mazdutide 9 mg group and 0% in the placebo group.

    Professor Linong Ji, the leading principal investigator of the study, Peking University People’s Hospital, stated, “As a chronic disease with a complex etiology, obesity requires public awareness of long-term treatment and management. China faces a high prevalence of obesity, with obese individuals bearing a significant burden of cardiometabolic diseases. Those with a BMI exceeding 32.5 kg/m², often experience an even greater cardiometabolic burden. This patient population requires special attention in clinical weight management and metabolic syndrome prevention. According to current Chinese clinical guidelines, metabolic surgery is often considered a first-line treatment for such patients. Extensive clinical evidence on GLP-1 receptor agonists demonstrates that the weight-loss efficacy of these drugs is dose-dependent. Therefore, developing pharmacological treatments tailored to moderate-to-severe obesity could offer new therapeutic options for this group. The investigators of this study and I are delighted that this study met both its primary endpoints and all key secondary endpoints. Mazdutide 9 mg has once again demonstrated outstanding weight-loss efficacy, multiple metabolic benefits and favorable safety. We hope mazdutide 9 mg will successfully achieve regulatory approval, supporting stratified weight management for China’s obese population and enabling more personalized treatment approaches.”

    Dr. Lei Qian, Chief R&D Officer of General Biomedicine of Innovent, stated, “Mazdutide 9 mg is currently the only GLP-1 receptor agonist that achieves over 20% weight loss in obese adults without T2D after 1 year of treatment with just a 2-step dose titration. Its development provides evidence-based medical support for effective weight management in Chinese patients with moderate-to-severe obesity, offering an alternative to metabolic surgery. We plan to submit a supplemental application for mazdutide 9 mg in the near future, aiming to deliver this innovative treatment to patients as soon as possible. Concurrently, the lifecycle management plan for mazdutide continues to expand its boundaries, exploring further therapeutic potentials. We are developing mazdutide for other indications on the basis of scientific evidence and unmet medical needs. Innovent will continue to strategically build our next-generation product pipeline in the cardiovascular and metabolic (CVM) field, and help people’s pursuit of a healthy life.”

    Mazdutide has earned widespread recognition supported by robust data set. Its Phase 2 clinical trial in Chinese subjects with overweight or obesity was selected by Nature Communications as one of the 50 most important studies in translational and clinical research and highlighted as Editor’s Choice. Additionally, mazdutide was listed among the “Top 10 Most Anticipated Drug Launches of 2025” by the FIERCE Pharma.

    Furthermore, clinical findings on mazdutide have been featured in top-tier international journals such as The New England Journal of Medicine, Nature Communications, Diabetes Care, and eClinicalMedicine, as well as presented at leading scientific conferences including the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) annual meetings. Notably, mazdutide is the first innovative drug in China’s endocrinology and metabolism field to have clinical results published in The New England Journal of Medicine, underscoring its significant clinical value.

    About Mazdutide

    Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a dual GCG/GLP-1 receptor agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, serum uric acid, liver enzymes, liver fat content and improved insulin sensitivity.

    Innovent has currently conducted or completed seven Phase 3 clinical studies of mazdutide, including:

    • GLORY-1: A Phase 3 clinical study conducted in Chinese adults with overweight of obesity;
    • GLORY-2: A Phase 3 clinical study conducted in Chinese adults with moderately to severely obesity;
    • DREAMS-1: A Phase 3 clinical study conducted in Chinese adults with untreated type 2 diabetes;
    • DREAMS-2: A Phase 3 clinical study comparing mazdutide versus dulaglutide in Chinese adults with type 2 diabetes who have poor glycemia control with oral medication;
    • DREAMS-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity;
    • GLORY-3: A Phase 3 clinical study comparing mazdutide versus semaglutide 2.4mg in Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD);
    • GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity;

    Among these, the first five Phase 3 clinical studies have all met their primary endpoints, while the remaining two Phase 3 studies are still ongoing.

    In addition, several clinical studies of mazdutide are ongoing in adolescents with obesity, patients with metabolic dysfunction-associated steatohepatitis (MASH),heart failure with preserved ejection fraction (HFpEF) etc.

    Mazdutide has received NMPA approval for two indications:

    First Indication: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of:

    • BMI ≥ 28 kg/m² (obesity); or
    • BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome).

    Second Indication: For glycemic control in adults with type 2 diabetes.

    Monotherapy:

    For adults with type 2 diabetes who have inadequate glycemic control despite diet and exercise interventions.

    Combination Therapy:

    For adults with T2D who still have poor glycemic control despite:

    • Diet and exercise, plus Metformin and/or sulfonylureas;
    • Diet and exercise, plus Metformin and/or SGLT2 inhibitors (SGLT2i).

    About Innovent Biologics

    Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

    Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

    Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

    Forward-looking statement

    This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

    These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

    Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

    SOURCE Innovent Biologics

    Continue Reading

  • Galaxy Watch Series Health Features Help Save Lives – Samsung Global Newsroom

    Galaxy Watch Series Health Features Help Save Lives – Samsung Global Newsroom

    “I could have collapsed at any moment.”

    That’s how Roberto Gallart describes his health on the pivotal day his Galaxy Watch6 alerted him to a life-threatening heart condition. A single notification prompted him to seek…

    Continue Reading

  • Two thirds of women ‘put on too much or too little weight’ in pregnancy, study finds

    Two thirds of women ‘put on too much or too little weight’ in pregnancy, study finds

    A significant number of women are putting on too much or too little weight during pregnancy,…

    Continue Reading

  • 'Stranger Things' creators elevate creative elements for final season – Reuters

    1. ‘Stranger Things’ creators elevate creative elements for final season  Reuters
    2. ‘I’m at a Loss Without the Show’: Inside the Final Days of ‘Stranger Things’ and the Cast’s Heartbreaking Goodbyes  Variety
    3. ‘Stranger Things 5’ cast won’t…

    Continue Reading

  • Lenovo Delivers Record Quarterly Results, Marking Significant Progress in Hybrid AI

    Lenovo Delivers Record Quarterly Results, Marking Significant Progress in Hybrid AI

    November 20, 2025 – Lenovo Group Limited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported record results for the second quarter of fiscal year 2025/26, with overall group revenue reaching an all-time high of US$20.5 billion, up 15% year-on-year. Adjusted net income[1] grew 25% year-on-year to US$512 million, and adjusted net income margin expanded to 2.5%, driven by higher revenues. Together, these reflect the strength of the Group’s operational performance as they exclude the impact of non-cash fair value loss on warrants, notional interest on convertible bonds, and other non-cash items.

    The Group delivered double-digit year-on-year revenue growth across all main business groups and sales geographies. The AI-related revenue mix increased by 13 percentage points year-on-year, accounting for 30% of the Group’s total revenue this quarter. The growth was driven by high-double-digit revenue growth in AI Servers and triple-digit revenue growth in AI PCs, AI smartphones, and AI Services.

    These results are a testament to the Group’s clear strategy, operational excellence, and relentless innovation, reflecting not only the strength of its business today but also the resilience of its unique ‘Global/Local’ model and the vision of a company built to lead in the AI era. With the initial wave of infrastructure build-out in the AI era, the trend is evolving toward a more human- and enterprise-centric phase, as large language models become commoditized and user priorities shift toward personalization and private domain. This evolution is unlocking new opportunities across devices, hybrid infrastructure, and tailored solutions, and enabling the Group to expand its leadership in Personal AI and further deliver its value proposition in Enterprise AI.

    As the macroeconomic environment stabilizes, Lenovo remains committed to executing its Hybrid AI strategy and investing in innovation to deliver sustainable long-term returns to shareholders and make AI truly personalized.

    Lenovo’s Board of Directors declared an interim dividend of 8.50 HK cents per share.

    Chairman and CEO quote – Yuanqing Yang:

    “Capitalizing on the AI democratization trend, and thanks to our clear strategy, operational excellence and relentless innovation, Lenovo delivered another quarter of record performance, while making important progress in both Personal AI and Enterprise AI. We will continue to leverage our unique Global/Local model to navigate uncertainties and capture the tremendous Hybrid AI opportunities, and in doing so not only deliver sustainable long-term returns to our shareholders, but also make AI truly personalized for every individual and every enterprise.”

    Financial Highlights:

    Personal AI: Innovation strengthened market leadership, enriching ecosystem

    Lenovo is meeting growing consumer demand for hyper-personalization with its Personal AI strategy, ‘One Personal AI, Multiple Devices’. Launching globally at Tech World on January 6, 2026, Lenovo’s Personal AI super agent will seamlessly orchestrate across wearable and ambient devices to perceive, learn, and act like its user – ultimately becoming a true Personal AI Twin.

     Intelligent Devices Group (IDG) as the core engine for Lenovo’s Personal AI strategy, delivered strong Q2 FY25/26 results:

    • Overall IDG revenue grew nearly 12% year-on-year to US$15.1
    • PC market leadership was strengthened with a record 25.6% market share, further widening the lead over the number two player.
    • The PCs and smart devices business maintained its industry-leading profitability, driven by solid performance from high-margin segments.
    • AI PC penetration accelerated, accounting for 33% of all Lenovo PC shipments. Lenovo ranks #1 globally in the Windows AI PC segment with a 31.1% market share. Motorola smartphones delivered record volumes.
    • AI device momentum is particularly encouraging, with revenue mix from AI devices up 17 points year-on-year to 36%.

    Enterprise AI: Unleashing Hybrid AI Advantage, from infrastructure to solutions and services

    Lenovo is advancing its Enterprise AI strategy to help customers turn data and knowledge into actionable insights and value. The Group is well-positioned to drive Enterprise AI transformation and develop an AI Twin for customers. The shift from cloud-based AI training to on-premises and edge inferencing is expected to fuel greater growth in AI devices and AI applications, further expanding the company’s total addressable market.

     Infrastructure Solutions Group (ISG) as the key driver of Lenovo’s hybrid infrastructure, delivered strong growth in Q2 FY25/26:

    • Revenue grew 24% year-on-year to US$4.1 billion through the continued strong execution of its CSP (Cloud Service Provider) and Enterprise SMB dual strategy.
    • CSP business delivered record fiscal Q2 revenue.
    • The AI infrastructure business revenue achieved high double-digit year-on-year growth with a strong
    • Revenue from industry-leading liquid cooling solutions grew 154% year-on-year.
    • By optimizing Enterprise SMB business models to better serve the distinct needs of enterprise and SMB customers, the Group is confident that the infrastructure business will return to profitable growth soon.

     Solutions and Services Group (SSG) delivered solid growth in Q2 FY25/26, providing solutions and services for enterprises that leverage the Lenovo Hybrid AI Advantage:

    • SSG’s overall revenue grew 18% year-on-year to US$2.6 billion – marking 18 consecutive quarters of year-on-year revenue growth.
    • Operating margin was up 1.9 points year-on-year to over 22%.
    • Revenue from Support Services accelerated with double-digit year-on-year growth; Managed services and Projects and Solutions revenue mix was up 1 point year-on-year to almost 60% of SSG’s total revenue.
    • SSG is unleashing the power of Lenovo Hybrid AI Advantage, combining the AI factory, AI services, and the AI library of repeatable, scalable AI solutions for selected vertical industries and horizontal functions.

    Corporate and ESG highlights

    Achievements, announcements, and notable commitments over the past quarter include:

    [1] Note on adjusted net income:Adjusted measure was defined as financial metric by excluding net fair value changes on financial assets at fair value through profit or loss, amortization of intangible assets resulting from mergers and acquisitions, impairment and write-off of intangible assets, dilution gain on interest in an associate, fair value change on derivative financial liabilities relating to warrants, and notional interest on convertible bonds; and the corresponding income tax effects, if any.

    About Lenovo

    Lenovo is a US$69 billion revenue global technology powerhouse, ranked #196 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub. 

    Continue Reading